Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2020 |
| CAGR: | 4.9 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
Uterine cancer is one such cancer that presently shows an increasing incidence and mortality in the United States. In North America, healthcare providers and community programs help women achieve and maintain a healthy weight and get enough physical activity, which can reduce the risk for endometrial cancer, the most common uterine cancer. Promoting awareness of the need for timely evaluation of abnormal vaginal bleeding (between periods, after sex, or after menopause), an important symptom of uterine cancer increases the chance for early detection and treatment.
Recent breakthroughs have led to many advances in personalized approaches to various cancer types, including cancers of the female reproductive system, like uterine cancer and endometrial cancer. Across entire North America, especially in the United States, in all the healthcare organizations, gynecologic oncologists are available to provide the common people with a second opinion and design a treatment plan tailored to the tumor type, cancer stage, and individual needs. Such initiatives have a positive impact on the uterine cancer treatment and diagnostics market in North America.
Scope of the Report
Uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. Risk factors associated with this cancer are being overweight and starting periods at an early age.
| By Cancer Type | |
| Endometrial Cancer | |
| Uterine Sarcoma |
| By Procedure | |||||||
| |||||||
|
| Geography | |||||
|
Key Market Trends
Immunotherapy to Register Highest CAGR Over the Forecast Period
Immunotherapy is a type of treatment, in which drugs help an individual’s immune system to recognize the cancer cells and kill them. Immunotherapy is done for treating certain forms of endometrial cancer that has spread or recurred. Pembrolizumab (Keytruda) by Merck and Co. is a drug that is used for the immunotherapy. This drug had got the FDA approval in June 2018, and it is currently available in the market. This drug is given as an intravenous (IV) infusion every 3 weeks. Currently, there are several ongoing clinical trials meant for examining different drugs and their combinations in uterine cancer, including a combination of two immunotherapies, such as lenvatinib (Lenvima) and pembrolizumab.
Moreover, the demand for these therapies have also increased due to increased incidence of Uterine (cervix uteri) cancer globally. As per a 2018 report by the International Agency for Research on Cancer, the incidence of cervix uteri cancer is expected to increase from 569,000 in 2018 to more than 691,000 by 2030. This is expected to increase the demand for these therapies, which will help the market growth.
To understand key trends, Download Sample Report
Competitive Landscape
The uterine cancer diagnostics and treatment market is comprised of the global players that are having a focus on oncology division. Some of the major companies in this market include Merck & Co. Ltd, Pfizer Inc., AbbVie Inc., among others. With the rising research by pharmaceutical industry on the development of better therapeutics and diagnostics for various cancers, more companies are believed to enter the market in the coming future.
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rising Awareness about Uterine Diseases and the Available Therapies
-
4.2.2 Increasing Health Care Expenditure
-
4.2.3 Innovation in Drug Development and Subsequent Technological Advancements
-
-
4.3 Market Restraints
-
4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs and High Cost of Research and Development
-
4.3.2 High Cost Associated with the Treatment
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Cancer Type
-
5.1.1 Endometrial Cancer
-
5.1.2 Uterine Sarcoma
-
-
5.2 By Procedure
-
5.2.1 Treatment
-
5.2.1.1 Surgery
-
5.2.1.2 Immunotherapy
-
5.2.1.3 Radiation Therapy
-
5.2.1.4 Chemotherapy
-
5.2.1.5 Other Treatments
-
-
5.2.2 Diagnostics
-
5.2.2.1 Biopsy
-
5.2.2.2 Ultrasound
-
5.2.2.3 Hysteroscopy
-
5.2.2.4 Dilation and Curettage
-
5.2.2.5 Other Diagnostics
-
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 AbbVie Inc.
-
6.1.2 Becton, Dickinson and Company
-
6.1.3 Bristol-Myers Squibb Company
-
6.1.4 F. Hoffmann-La Roche Ltd
-
6.1.5 GlaxoSmithKline PLC
-
6.1.6 Merck & Co. Inc.
-
6.1.7 Novartis AG
-
6.1.8 Pfizer Inc.
-
6.1.9 Takeda Pharmaceutical Company Limited
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The North America Uterine Cancer Diagnostics & Treatment Market market is studied from 2018 - 2026.
What is the growth rate of North America Uterine Cancer Diagnostics & Treatment Market?
The North America Uterine Cancer Diagnostics & Treatment Market is growing at a CAGR of 4.9% over the next 5 years.
Who are the key players in North America Uterine Cancer Diagnostics & Treatment Market?
AbbVie Inc., Merck & Co. Ltd, Pfizer Inc., Becton Dickinson and Company, Bristol-Myers Squibb Company are the major companies operating in North America Uterine Cancer Diagnostics & Treatment Market.
